Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This project is a multi-center, prospective, randomized controlled clinical observation the
safety and efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of
advanced-stage epithelial ovarian cancer after cytoreductive surgery. Median recurrence-free
survival is the primary end points of this project.
Phase:
Phase 3
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Collaborators:
Affiliated Cancer Hospital of Shantou University Medical College Beijing Cancer Hospital Beijing Obstetrics and Gynecology Hospital Cancer Hospital of Guizhou Province Chinese PLA General Hospital Chongqing University Cancer Hospital First Affiliated Hospital of Chongqing Medical University First Affiliated Hospital, Sun Yat-Sen University Fourth Affiliated Hospital of Guangxi Medical University Hebei Medical University Fourth Hospital Henan Cancer Hospital Henan Provincial People's Hospital Obstetrics & Gynecology Hospital of Fudan University Peking Union Medical College Hospital Peking University People's Hospital RenJi Hospital Shandong Cancer Hospital and Institute Southern Medical University, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The Second Hospital of Hebei Medical University The Third Affiliated Hospital of Guangzhou Medical University The Third Xiangya Hospital of Central South University Third Affiliated Hospital, Sun Yat-Sen University Tianjin Medical University Cancer Institute and Hospital West China Second University Hospital Wuhan Union Hospital, China Wuhan University Xiangya Hospital of Central South University Xinqiao Hospital of Chongqing